Table 1.
Patient demographic and clinical characteristics by race
|
African-American |
White |
|||
|---|---|---|---|---|
| Number | (Percentage) | Number | (Percentage) | |
| Number of Subject | 834 | (20.9%) | 3,142 | (79.1%) |
| Demographics | ||||
| Age at study entry (year) * | 48.65 | (48.0, 49.0) | 51.04 | (50.72, 51.36) |
| 18–30 | 34 | (4.1%) | 90 | (2.8%) |
| 31–40 | 131 | (15.7%) | 341 | (10.8%) |
| 41–50 | 279 | (33.5%) | 851 | (27.1%) |
| >51 | 390 | (46.7%) | 1,860 | (59.2%) |
| Female gender | 553 | (65.2%) | 1,171 | (54.0%) |
| Non-commercial insurance | 343 | (40.5%) | 525 | (16.6%) |
| Clinical Characteristics | ||||
| A1C Level (%) * | 7.38 | (7.26, 7.50) | 6.85 | (6.81, 6.91) |
| A1C <7% | 440 | (51.9%) | 2,056 | (64.9%) |
| Number of A1C test * | 4.15 | (4.03, 4.26) | 3.76 | (3.70, 3.83) |
| OHA 6-month PDC * | 40% | (39%, 43%) | 50% | (49%, 51%) |
| OHA 6-month PDC ≥ 80% | 177 | (21.2%) | 1,031 | (32.8%) |
| Duration of OHA treatment (Year) | ||||
| 0–3 | 696 | (83.5%) | 2,693 | (85.7%) |
| 3–6 | 133 | (15.9%) | 441 | (14.0%) |
| 6–9 | 5 | (0.6%) | 8 | (0.3%) |
| Number of concurrent OHA medications | ||||
| 1 | 593 | (71.1%) | 2,155 | (68.6%) |
| 2 | 198 | (23.7%) | 802 | (25.5%) |
| ≥ 3 | 43 | 5.2%) | 185 | (5.9%) |
| OHA medication classes | ||||
| Biguanide Only | 314 | (37.4%) | 1,316 | (42.1%) |
| Sulfonylurea Only | 173 | (20.6%) | 358 | (11.1%) |
| Thiazolidinedione Only | 41 | (4.9%) | 206 | (6.6%) |
| Other | 7 | (0.8%) | 38 | (1.2%) |
| Multiple classes | 304 | (36.2%) | 1,205 | (38.6%) |
*
Data are mean (95% CI). All values are statistically significant at p < 0.001.